June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Impact of the vitreous configuration on the efficacy of quarterly, pro-re-nata and monthly treatment in multicenter trials evaluating ranibizumab for neovascular age-related macular degeneration
Author Affiliations & Notes
  • Sebastian Waldstein
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Ulrike Mayr-Sponer
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Markus Ritter
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Michael Kundi
    Institute of Environmental Health, Medical University of Vienna, Vienna, Austria
  • Christian Simader
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Ursula Schmidt-Erfurth
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Footnotes
    Commercial Relationships Sebastian Waldstein, None; Ulrike Mayr-Sponer, None; Markus Ritter, None; Michael Kundi, None; Christian Simader, None; Ursula Schmidt-Erfurth, Alcon (C), Bayer Healthcare (C), Novartis (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3818. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sebastian Waldstein, Ulrike Mayr-Sponer, Markus Ritter, Michael Kundi, Christian Simader, Ursula Schmidt-Erfurth, ; Impact of the vitreous configuration on the efficacy of quarterly, pro-re-nata and monthly treatment in multicenter trials evaluating ranibizumab for neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3818.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Intravitreal administration of antiangiogenic drugs is the mainstay of current treatment of exudative macular diseases. However, the impact of the vitreous on the relevant pharmacokinetic mechanisms is unclear. The purpose of this study was to investigate the influence of the configuration of the vitreomacular interface (VMI) on the efficacy of quarterly, pro re nata (PRN) and monthly dosing of ranibizumab in the treatment of neovascular age-related macular degeneration (AMD).

Methods: Standardized monthly optical coherence tomography (OCT) examinations of 486 treatment-naïve patients, enrolled in two separate 12-month prospective randomized multicenter trials, were analyzed for the configuration of the VMI by certified graders of the Vienna Reading Center. Only patients with 10 or more available OCT-examinations, including baseline and month 12, were eligible for the analysis. The individual VMI readings from each visit were integrated to divide all patients into one of the following categories: (1) persistent vitreomacular adhesion (VMA); (2) progressive release of vitreomacular adhesion (RVA); (3) complete posterior vitreous detachment (PVD).

Results: At month 12, the mean change in best-corrected visual acuity (BCVA) from baseline was as follows: Quarterly treatment (n=163): VMA -0.3, RVA +3.2, PVD +4.7 letters; PRN treatment (n=128): VMA +6.3, RVA +4.3, PVD +3.7 letters; monthly treatment (n=84): VMA +7.5, RVA +12.7, PVD +4.9 letters. Quarterly treatment was non-inferior to monthly treatment in patients with PVD, p=0.001. Monthly treatment was superior to quarterly treatment in patients with VMA and RVA, p=0.035. In the PRN regimen, patients with PVD required significantly less dosing (mean 4.8 injections) compared to VMA and RVA (mean 5.3/6.6 injections, p<0.001). The functional outcomes of monthly treatment of patients with VMA and RVA surpassed those of all others.

Conclusions: The configuration of the VMI has a significant impact on the efficacy of therapeutic regimens. Patients with PVD appear to be less sensitive to dosing variations, while patients with VMA and RVA may derive optimal benefit from continuous intensive treatment. Our findings may serve as a base for individualized treatment decisions in neovascular AMD and potentially other indications.

Keywords: 412 age-related macular degeneration • 763 vitreous • 453 choroid: neovascularization  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×